Literature DB >> 26327166

Predictors of Red Cell Alloimmunization in Kurdish Multi Transfused Patients with Hemoglobinopathies in Iraq.

Muqdad M N Al-Mousawi1, Nasir A S Al-Allawi2, Rubad Alnaqshabandi3.   

Abstract

Hemoglobinopathies are significant health problems in Iraq, including its Northern Kurdistan region. One of the essential components of management of these disorders is regular lifelong blood transfusions. The latter is associated with several complications including red cell alloimmunization. No study has looked at the frequency of alloimmunization and its associations in the country. To address the latter issue, 401 multi transfused patients [311 with β-thalassemia (β-thal) syndrome and 90 with sickle cell disease], registered at a large thalassemia care center in Iraqi Kurdistan had their records reviewed, and their sera tested for atypical antibodies using screening and extended red cell panels. Red cell alloimmunization was detected in 18 patients (4.5%) with a total of 20 alloantibodies, while no autoantibodies were detected. The most frequent alloantibody was anti-E, followed by anti-D, anti-K, anti-C(w), anti-C, anti-c and anti-Le(a). Ethnicity was an important predictor of alloimmunization, while age at start of transfusion (>2 vs. ≤2 years) (p = 0.005), Rhesus D (RhD) negative status (p = 0.0017) and history of previous transfusion reactions (p = 0.007) showed a statistically significant higher rate of alloimmunization. However, patients' age, gender, number of units transfused, underlying diagnosis and splenectomy were not significantly associated with alloimmunization. Based on our observations, measures to reduce alloimmunization rates may include extended matching for Rhesus and Kell antigens and early initiation of blood transfusions.

Entities:  

Keywords:  Alloimmunization; Iraq; hemoglobinopathies; sickle cell disease; β-thalassemia (β-thal)

Mesh:

Substances:

Year:  2015        PMID: 26327166     DOI: 10.3109/03630269.2015.1077460

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  6 in total

1.  Absence of the spleen and the occurrence of primary red cell alloimmunization in humans.

Authors:  Dorothea Evers; Johanna G van der Bom; Janneke Tijmensen; Masja de Haas; Rutger A Middelburg; Karen M K de Vooght; Daan van de Kerkhof; Otto Visser; Nathalie C V Péquériaux; Francisca Hudig; Jaap Jan Zwaginga
Journal:  Haematologica       Date:  2017-04-14       Impact factor: 9.941

2.  Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database.

Authors:  Matthew S Karafin; Matt Westlake; Ronald G Hauser; Christopher A Tormey; Philip J Norris; Nareg H Roubinian; Yanyun Wu; Darrell J Triulzi; Steve Kleinman; Jeanne E Hendrickson
Journal:  Br J Haematol       Date:  2018-04-19       Impact factor: 6.998

3.  Alloimmunization and autoimmunization in adult transfusion-dependent thalassemia patients: a report from a comprehensive center in Israel.

Authors:  Idit Pazgal; Vered Yahalom; Bruria Shalev; Pia Raanani; Pinhas Stark
Journal:  Ann Hematol       Date:  2020-06-02       Impact factor: 3.673

4.  The Rh blood group system and its role in alloimmunization rate among sickle cell disease and sickle thalassemia patients in Iran.

Authors:  Mohammad Ali Jalali Far; Arezoo Oodi; Naser Amirizadeh; Mahshid Mohammadipour; Bijan Keikhaei Dehdezi
Journal:  Mol Genet Genomic Med       Date:  2021-02-06       Impact factor: 2.183

5.  The Role of the Immunological Synapse in Differential Effects of APC Subsets in Alloimmunization to Fresh, Non-stored RBCs.

Authors:  Amanda L Richards; Kathryn Sheldon; Xiaoping Wu; David R Gruber; Krystalyn E Hudson
Journal:  Front Immunol       Date:  2018-10-05       Impact factor: 7.561

6.  Study of Frequency and Characteristics of Red Blood Cell Alloimmunization in Thalassemic Patients: Multicenter Study from Palestine.

Authors:  Adham Abu Taha; Ahmad Yaseen; Sa'd Suleiman; Omar Abu Zenah; Hammam Ali; Rania Abu Seir; Khaled Younis
Journal:  Adv Hematol       Date:  2019-11-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.